Statera BioPharma (FRA:7CB) LT-Debt-to-Total-Asset: 0.05 (As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma LT-Debt-to-Total-Asset?

Statera BioPharma FRA:7CB 20 LT-Debt-to-Total-Asset is 0.05 as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Statera BioPharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.05.

Statera BioPharma's long-term debt to total assets ratio declined from Sep. 2021 (0.14) to Sep. 2022 (0.05). It may suggest that Statera BioPharma is progressively becoming less dependent on debt to grow their business.

Statera BioPharma  (FRA:7CB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Statera BioPharma LT-Debt-to-Total-Asset Related Terms

Statera BioPharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma LT-Debt-to-Total-Asset Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
LT-Debt-to-Total-Asset
0.00 0.07 0.54

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.14 0.54 0.06 0.06 0.05
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma LT-Debt-to-Total-Asset Calculation

Statera BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )/Total Assets (A: Dec. 2021 )
=10.116/18.735
=

Statera BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )/Total Assets (Q: Sep. 2022 )
=0.693/12.876
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.05 mean?
Statera BioPharma (FRA:7CB) has a LT-Debt-to-Total-Asset of 0.05 as of Sep. 2022. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's LT-Debt-to-Total-Asset too high?
Statera BioPharma's current LT-Debt-to-Total-Asset is 0.05. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's LT-Debt-to-Total-Asset compare to NRBO and PALI?
Statera BioPharma's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current LT-Debt-to-Total-Asset of 0.05. The current LT-Debt-to-Total-Asset is 0.05. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current LT-Debt-to-Total-Asset is 0.05 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price